<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02316236</url>
  </required_header>
  <id_info>
    <org_study_id>XJH-A-2014-6-22-01</org_study_id>
    <nct_id>NCT02316236</nct_id>
  </id_info>
  <brief_title>Dexmedetomidine to Improve Outcomes During Emergence From Retroperitoneal Laparoscopic Surgery</brief_title>
  <acronym>DEALS</acronym>
  <official_title>Effect of Dexmedetomidine on Outcomes During Emergence From Retroperitoneal Laparoscopic Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fourth Military Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fourth Military Medical University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is to observe whether dexmedetomidine could reduce agitation during emergence from
      general anesthesia in patients undergoing retroperitoneal laparoscopic surgery.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Agitation during emergence is frequent after retroperitoneal urologic surgery.
      Dexmedetomidine is alpha-2 receptor agonist which shows sedative and algesic effect. In this
      study we will compare the effect of dexmedetomidine given by different protocols on emergence
      agitation.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>December 2014</start_date>
  <completion_date type="Anticipated">December 2016</completion_date>
  <primary_completion_date type="Anticipated">December 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Richmond Score</measure>
    <time_frame>From end of sevoflurane inhalation to departure from PACU, an expected average of 1 hour</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cough score</measure>
    <time_frame>From end of sevoflurane inhalation to departure from PACU, an expected average of 1 hour</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to awake</measure>
    <time_frame>From end of sevoflurane inhalation to departure from PACU, an expected average of 1 hour</time_frame>
    <description>time to open eyes to verbal command</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Anesthesia</condition>
  <arm_group>
    <arm_group_label>dexmedetomidine loading dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>dexmedetomidine is given at load dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>dexmedetomidine sustaining dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>dexmedetomidine is given at sustaining dose</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>dexmedetomidine</intervention_name>
    <description>an alpha-2 receptor agonist</description>
    <arm_group_label>dexmedetomidine loading dose</arm_group_label>
    <arm_group_label>dexmedetomidine sustaining dose</arm_group_label>
    <other_name>dex</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>loading dose</intervention_name>
    <description>0.8ug/kg of dexmedetomidine is given in 10 minutes</description>
    <arm_group_label>dexmedetomidine loading dose</arm_group_label>
    <other_name>LD</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>sustaining dose</intervention_name>
    <description>0.4ug/kg/min of dexmedetomidine is given</description>
    <arm_group_label>dexmedetomidine sustaining dose</arm_group_label>
    <other_name>SD</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients scheduled for retroperitoneal laparoscopic surgery

          -  Patients with written informed consent

        Exclusion Criteria:

          -  Patients with difficulty of communication

          -  Patients with risk of obstructive sleeping apnea syndrome
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lize Xiong, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Fourth Military Medical University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Hailong Dong, PhD</last_name>
    <phone>86-29-84775337</phone>
    <email>hldong369@hotmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Xijing Hospital</name>
      <address>
        <city>Xi'an</city>
        <state>Shaanxi</state>
        <zip>710032</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Qianqian Fan, MD</last_name>
      <phone>86-29-84775343</phone>
      <email>fanqq@126.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <results_reference>
    <citation>Yang S, Lee H. A dose-finding study of preoperative intravenous dexmedetomidine in children's emergence delirium after epiblepharon surgery. Eur J Ophthalmol. 2014 May-Jun;24(3):417-23. doi: 10.5301/ejo.5000396. Epub 2013 Nov 29.</citation>
    <PMID>24338578</PMID>
  </results_reference>
  <results_reference>
    <citation>Kim SY, Kim JM, Lee JH, Song BM, Koo BN. Efficacy of intraoperative dexmedetomidine infusion on emergence agitation and quality of recovery after nasal surgery. Br J Anaesth. 2013 Aug;111(2):222-8. doi: 10.1093/bja/aet056. Epub 2013 Mar 22.</citation>
    <PMID>23524149</PMID>
  </results_reference>
  <results_reference>
    <citation>Ibacache ME, Mu√±oz HR, Brandes V, Morales AL. Single-dose dexmedetomidine reduces agitation after sevoflurane anesthesia in children. Anesth Analg. 2004 Jan;98(1):60-3, table of contents.</citation>
    <PMID>14693585</PMID>
  </results_reference>
  <verification_date>January 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 8, 2014</study_first_submitted>
  <study_first_submitted_qc>December 10, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 12, 2014</study_first_posted>
  <last_update_submitted>January 13, 2016</last_update_submitted>
  <last_update_submitted_qc>January 13, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 14, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Fourth Military Medical University</investigator_affiliation>
    <investigator_full_name>Zhihong LU</investigator_full_name>
    <investigator_title>Dr</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexmedetomidine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

